Verrica Pharmaceuticals
VRCA
42 hedge funds and large institutions have $137M invested in Verrica Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 4 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
31% more capital invested
Capital invested by funds: $105M → $137M (+$32M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 41 → 42 (+1)
0.09% more ownership
Funds ownership: 3.51% → 3.6% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.43M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$964K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$689K |
| 4 |
BlackRock
New York
|
+$678K |
| 5 |
State Street
Boston,
Massachusetts
|
+$302K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.65M |
| 2 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$652K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$233K |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$126K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$70.6K |
VRCA Hedge Fund Activity: Q3 2019 in Review
42 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2019, worth a combined $137M — up 31% from $105M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VRCA positions and 4 closed out — a net gain of 1 holder — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $1.43M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.65M sold.
- 42 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2019, up from 41 in Q2 2019.
- Funds reported $137M of Verrica Pharmaceuticals stock for Q3 2019, up 31% quarter-over-quarter.
- 5 funds opened new Verrica Pharmaceuticals positions in Q3 2019 and 4 closed out, a net change of +1 holder.
- The largest Verrica Pharmaceuticals buyer in Q3 2019 was Schonfeld Strategic Advisors, an estimated $1.43M added.
- The largest Verrica Pharmaceuticals seller in Q3 2019 was Point72 Asset Management, an estimated $1.65M sold.
Based on aggregated 13F filings for Q3 2019.